Valneva (VALN) has released an update.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Valneva has announced promising three-year data for its single-dose chikungunya vaccine, IXCHIQ®, which maintains strong antibody levels in both younger and older adults. The vaccine is approved in the US, Europe, and Canada, and Valneva is working to expand its use to adolescents and in regions with limited vaccine access. Supported by significant funding, the company is also pursuing marketing authorization in Brazil and aims to broaden access in low and middle-income countries.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.